Briumvi (ublituximab) is indicated for the treatment of relapsing forms Applicable Billing Codes (HCPCS/CPT Codes). CPT/HCPCS Codes
The BRIUMVI J-Code is now available for dates of service on or after J J2329, Injection, ublituximab-xiiy, 1 mg
Find out the BRIUMVI J-Code (J2329) for billing and coding purposes and access other resources for coverage and reimbursement of BRIUMVI, a treatment for relapsing forms of multiple sclerosis. Learn about the indications, warnings, precautions, and adverse events of BRIUMVI.
BRIUMVI (ublituximab-xiiy). J Code: J2329. Drug Order: □ Loading Dose. First Infusion: Administer 150 mg IV over 4 hours. Doses authorized: 2 doses (4 150
TG's Q2 update also highlighted that the company received a permanent J-Code for Briumvi from the U.S. Centers of Medicare Medicaid Services
[subcutaneous]), Briumvi (ublituximab) Claims received with HCPCS Code J3590 will pend with Remark Code PRR and will be adjudicated in.
The BRIUMVI J-Code is now available for dates of service on or after J J2329, Injection, ublituximab-xiiy, 1 mg. Welcome to BRIUMVI Patient Support!
BRIUMVI is a Immunology drug manufactured by TG THERAPEUTICS, INC. and administered via the Intravenous route of administration. The J Code: J2329 is
Under the Healthcare Common Procedure Coding System (HCPCS), the BRIUMVI J-Code (J2329) will become effective J. J-Code for BRIUMVI
R.